Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions-Reference-Cited by-同舟云学术

Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions

Published:2018-06-21 Issue:9 Volume:84 Page:1941-1949
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Stopfer Peter¹^ORCID,Giessmann Thomas¹,Hohl Kathrin¹,Hutzel Sabine¹,Schmidt Sven¹,Gansser Dietmar¹,Ishiguro Naoki²,Taub Mitchell E.³,Sharma Ashish¹,Ebner Thomas¹,Müller Fabian¹⁴

Affiliation:

1. Boehringer Ingelheim Pharma GmbH & Co. KG; Birkendorfer Str. 65 88397 Biberach an der Riss Germany

2. Kobe Pharma Research Institute; Nippon Boehringer Ingelheim Co. Ltd.; Chuo-ku Kobe City Japan

3. Boehringer Ingelheim Pharmaceuticals Inc.; 900 Ridgebury Road Ridgefield CT 06877 USA

4. Friedrich-Alexander-Universität Erlangen-Nürnberg; Institute of Experimental and Clinical Pharmacology and Toxicology; Fahrstr. 17 91054 Erlangen Germany

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13609/fullpdf

Reference24 articles.

1. Transporters and drug-drug interactions: important determinants of drug disposition and effects;König;Pharmacol Rev,2013

2. Membrane transporters in drug development;Giacomini;Nat Rev Drug Discov,2010

3. Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions;Zolk;Clin Pharmacol Ther,2011

4. Emerging transporters of clinical importance: an update from the International Transporter Consortium;Hillgren;Clin Pharmacol Ther,2013

5. US-FDA Guidance for industry: clinical drug interaction studies - study design, data analysis, and clinical implications (draft guidance) 2017 https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase I drug–drug interaction study to assess the effect of futibatinib on P‐gp and BCRP substrates and of P‐gp inhibition on the pharmacokinetics of futibatinib;Clinical and Translational Science;2024-09

2. Innovative Approaches to Optimize Clinical Transporter Drug–Drug Interaction Studies;Pharmaceutics;2024-07-26

3. Transporter-mediated drug-drug interactions: regulatory guidelines, in vitro and in vivo methodologies and translation, special populations, and the blood-brain barrier;Drug Metabolism Reviews;2024-07-05

4. Expanding Role of Endogenous Biomarkers for Assessment of Transporter Activity in Drug Development: Current Applications and Future Horizon;Pharmaceutics;2024-06-25

5. Utilising Endogenous Biomarkers in Drug Development to Streamline the Assessment of Drug–Drug Interactions Mediated by Renal Transporters: A Pharmaceutical Industry Perspective;Clinical Pharmacokinetics;2024-06